School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...
ARS Pharma will host a webinar for school nurses and administrators about neffy and the neffyinSchools program on January 22, 2025. Participants are encouraged to register here. For more ...
and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis can ...
Hosted on MSN13d
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary ...
In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a ...
and CEO of ARS Pharma.“ neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis ...
Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma, will present on Wednesday, January 15, 2025, at 7:30 a.m. PT. Company management will also participate in one-on-one meetings with ...
ARS Pharmaceuticals Files for Approval of neffy® (Epinephrine Nasal Spray) 2 mg in Canada and the UK
The licensing deal includes substantial upfront and milestone payments. ARS Pharma is also exploring using its intranasal epinephrine technology for treating chronic urticaria, with a Phase 2b ...
neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). In November 2024, ARS Pharma announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback